Redcare Pharmacy's New CFO Faces Crucial Margin Test After Stellar Sales

Redcare Pharmacy's Q1 revenue beat forecasts, driven by 35% Rx growth. New CFO faces challenge of turning sales into profit amid heavy investment cycle.

Redcare Pharmacy's stock has been on a wild ride, surging roughly 51% over the past month to €50.60. Yet this rally masks a deeper challenge for the newly installed leadership team: translating explosive top-line growth into sustainable profitability. All eyes are now on the company's upcoming interim statement on May 6, which will provide the first full financial snapshot under new CFO Hendrik Krampe.

The preliminary figures for the first quarter of 2026 set a high bar. Group revenue jumped 18.3% to €848 million, surpassing both analyst consensus and the company's own full-year growth forecast of 13-15%. The prescription business was the powerhouse, with global Rx sales climbing 35%. In its home German market, the growth rate accelerated dramatically to 55%, helping to expand Redcare's active customer base to 14.2 million users.

This operational strength arrives alongside a potential structural tailwind from Berlin. An expert commission has recommended raising statutory co-payments for prescription medicines by 50%, from €5-10 to €7.50-15. Health Minister Nina Warken has pledged to advance the corresponding legislation swiftly. Felix Dennl of Bankhaus Metzler argues that higher out-of-pocket costs will drive price-sensitive patients toward more affordable channels, a trend from which online pharmacies like Redcare stand to benefit disproportionately. The company already commands a dominant 67% share of the German online prescription market, a position solidified after competitor Rossmann explicitly ruled out entering the Rx segment.

However, this growth comes at a cost that has weighed heavily on the share price. Since the start of the year, the stock is down approximately 25%, trading more than 60% below its 52-week high of €136.20. The pressure stems from a significant investment cycle currently underway. The company is building a new logistics center in Pilsen, Czech Republic, designed to increase annual capacity by 15 million packages. This capital expenditure program is compressing margins, leading management to lower its medium-term EBITDA margin target from over 8% to more than 5%. For 2026, the company is targeting an adjusted EBITDA margin of at least 2.5%, with capital expenditures expected to fall below 2% of sales after the investment peak passes.

The task of steering through this high-investment phase now falls to Hendrik Krampe, whose appointment was formally confirmed at the Annual General Meeting in mid-April. Krampe brings over three decades of experience, including an eleven-year stint at Amazon's European headquarters in Luxembourg, where he spent eight years as Finance Director for the European marketplace business. His expertise in scaling online platforms is seen as a direct fit for Redcare's growth strategy. He is joined by three newly elected supervisory board members: Anja Hendel, Max Müller, and Peter Schmid von Linstow.

While the regulatory environment offers promise, it is not without complications. Plans to raise the fixed fee per medication package for pharmacists from €8.35 to €9.50—unchanged for 13 years—are clouded by a simultaneous proposal from Minister Warken to increase the mandatory discount pharmacies must give to statutory health insurers. Pharmacy associations believe this move would largely neutralize the positive effect of the fee increase.

Analyst sentiment remains cautiously optimistic despite the near-term margin pressure. Jefferies maintains a €150 price target, praising the strong start to the year. Deutsche Bank also recommends the stock, citing Redcare's growing market share in the e-prescription segment. The May 6 report will be the first real test for Krampe and the refreshed leadership team, revealing whether profitability metrics can keep pace with the impressive sales momentum.